Matinas BioPharma Holdings, Inc. (MTNB) stock
MTNBNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$0.91+0.05 (+6.35%)
Close on Nov 18, 2026Market cap $13.37MP/E –Yield –
Matinas BioPharma r&d expenses
Research and development expenses are spending on new products and technology.
Matinas BioPharma's R&D Expenses for the twelve months ending Dec 31, 2025 was $85.00K, down 99.3% year over year. For fiscal 2025 it was $85.00K, down 99.3% from the year before. Over ten years it grew -33.8% a year on average. The highest annual figure on record is $16.68M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $85.00K | -99.3% |
| FY2024 | Dec 31, 2024 | $11.43M | -21.1% |
| FY2023 | Dec 31, 2023 | $14.49M | -13.1% |
| FY2022 | Dec 31, 2022 | $16.68M | +14.4% |
| FY2021 | Dec 31, 2021 | $14.58M | +1.6% |
| FY2020 | Dec 31, 2020 | $14.36M | +27.8% |
| FY2019 | Dec 31, 2019 | $11.23M | +65.5% |
| FY2018 | Dec 31, 2018 | $6.79M | -24.7% |
| FY2017 | Dec 31, 2017 | $9.01M | +128.3% |
| FY2016 | Dec 31, 2016 | $3.95M | -25.4% |
| FY2015 | Dec 31, 2015 | $5.29M | +2.3% |
| FY2014 | Dec 31, 2014 | $5.18M | +193.8% |
| FY2013 | Dec 31, 2013 | $1.76M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | $0 | -100.0% |
| Q3 FY2025 | Sep 30, 2025 | $0 | -100.0% |
| Q2 FY2025 | Jun 30, 2025 | $0 | -100.0% |
| Q1 FY2025 | Mar 31, 2025 | $85.00K | -97.5% |
| Q4 FY2024 | Dec 31, 2024 | $2.38M | -35.2% |
| Q3 FY2024 | Sep 30, 2024 | $2.24M | -32.0% |
| Q2 FY2024 | Jun 30, 2024 | $3.37M | -5.3% |
| Q1 FY2024 | Mar 31, 2024 | $3.45M | -13.2% |
| Q4 FY2023 | Dec 31, 2023 | $3.67M | -5.2% |
| Q3 FY2023 | Sep 30, 2023 | $3.30M | -11.1% |
| Q2 FY2023 | Jun 30, 2023 | $3.56M | -13.8% |
| Q1 FY2023 | Mar 31, 2023 | $3.97M | -20.2% |
| Q4 FY2022 | Dec 31, 2022 | $3.87M | -8.8% |
| Q3 FY2022 | Sep 30, 2022 | $3.71M | -19.8% |
| Q2 FY2022 | Jun 30, 2022 | $4.13M | +66.4% |
| Q1 FY2022 | Mar 31, 2022 | $4.98M | +53.6% |
| Q4 FY2021 | Dec 31, 2021 | $4.24M | +20.3% |
| Q3 FY2021 | Sep 30, 2021 | $4.62M | +38.5% |
| Q2 FY2021 | Jun 30, 2021 | $2.48M | -27.3% |
| Q1 FY2021 | Mar 31, 2021 | $3.24M | -20.7% |
| Q4 FY2020 | Dec 31, 2020 | $3.53M | +3.1% |
| Q3 FY2020 | Sep 30, 2020 | $3.34M | +24.9% |
| Q2 FY2020 | Jun 30, 2020 | $3.41M | +20.6% |
| Q1 FY2020 | Mar 31, 2020 | $4.09M | +76.6% |
| Q4 FY2019 | Dec 31, 2019 | $3.42M | +102.1% |
| Q3 FY2019 | Sep 30, 2019 | $2.67M | +93.6% |
| Q2 FY2019 | Jun 30, 2019 | $2.83M | +85.8% |
| Q1 FY2019 | Mar 31, 2019 | $2.31M | +5.6% |
| Q4 FY2018 | Dec 31, 2018 | $1.69M | -26.4% |
| Q3 FY2018 | Sep 30, 2018 | $1.38M | -31.5% |
| Q2 FY2018 | Jun 30, 2018 | $1.52M | -34.2% |
| Q1 FY2018 | Mar 31, 2018 | $2.19M | -8.0% |
| Q4 FY2017 | Dec 31, 2017 | $2.30M | +48.5% |
| Q3 FY2017 | Sep 30, 2017 | $2.01M | +141.0% |
| Q2 FY2017 | Jun 30, 2017 | $2.31M | – |
| Q1 FY2017 | Mar 31, 2017 | $2.38M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.55M | – |
| Q3 FY2016 | Sep 30, 2016 | $835.31K | – |
See a number that looks wrong?